Voranigo: Cost, Side Effects, Uses, Dosage, and More

What Is Voranigo?

Voranigo is an oral prescription medication that blocks mutant forms of two enzymes:
isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2).
In certain gliomas, IDH mutations help tumor cells grow by producing an abnormal “oncometabolite” (2-hydroxyglutarate).
Voranigo aims to shut down that abnormal signaling so tumor growth slows.

It’s considered a targeted therapymeaning it’s designed for tumors with a particular molecular feature.
That’s why tumor genetic testing (on the tumor tissue) is a central part of deciding if Voranigo even makes sense.

Voranigo Uses: What Does It Treat?

Voranigo is indicated for adults and pediatric patients ages 12 and older with:

• Grade 2 astrocytoma or grade 2 oligodendroglioma
• with a susceptible IDH1 or IDH2 mutation
• after surgery (including biopsy, subtotal resection, or gross total resection)

A key practical point: in the major clinical trial that supported approval, many patients were in a “watchful waiting” phase after surgery
meaning they weren’t starting radiation and/or chemotherapy right away. Voranigo was studied as a way to delay progression
and postpone the next major treatment step for some people.

Who Decides If It’s Right for You?

Typically, an oncology team (often including a neuro-oncologist) weighs:
tumor type, tumor genetics (IDH mutation status), MRI behavior, symptoms, seizure control, age, fertility plans,
and your overall treatment timeline (for example, whether radiation is needed soon or can be delayed).

How Well Does Voranigo Work?

In a large phase 3 trial (INDIGO), people with residual or recurrent grade 2 IDH-mutant glioma who had surgery as their only prior treatment
were randomized to receive vorasidenib or placebo.

The headline result: the median progression-free survival (time until the tumor worsened on imaging or death) was
27.7 months with vorasidenib versus 11.1 months with placebo.
The trial also found a meaningful delay in the time to the next anticancer intervention.

What that means in real life: Voranigo isn’t described as a cure. It’s a tool that, for some people, can buy timeoften time with fewer
treatment burdens than immediate radiation/chemo. And in brain tumors, time matters… because life doesn’t pause politely.

Voranigo Dosage: Typical Dosing and How to Take It

Voranigo is taken by mouth once daily. It can be taken with or without food.
Tablets should be swallowed whole (no splitting, crushing, or chewingsorry, no “I’ll just halve it” DIY pharmacology).

Standard Dosage (Adults)

• 40 mg orally once daily

Standard Dosage (Pediatric Patients Ages 12+)

• ≥ 40 kg: 40 mg orally once daily
• < 40 kg: 20 mg orally once daily

Missed Dose and Vomiting Rules (The “Don’t Panic” Section)

• If you miss a dose: take it as soon as possible within 6 hours.
  If it’s been more than 6 hours, skip it and take the next dose at the usual time.
• If you vomit after taking it: do not take an extra replacement dose.
  Take the next dose at the normal time the following day.

How Long Do You Take Voranigo?

In studies and prescribing guidance, treatment continues until disease progression or unacceptable toxicity.
In plain English: you keep going as long as it’s helping and side effects remain manageable.

Side Effects of Voranigo

All medications have side effects. Cancer medications, in particular, love to come with fine print.
The most important thing about Voranigo side effects is this: liver test elevations are the big safety headline.
Your liver is basically the body’s chemical processing plantgreat at its job, but not a fan of surprise overtime.

Most Common Side Effects

In the key clinical trial, common side effects (all grades) included:

• Fatigue (feeling wiped out)
• COVID-19 (reported during the trial period)
• Musculoskeletal pain (aches, back pain, joint pain)
• Diarrhea
• Constipation
• Abdominal pain/discomfort
• Decreased appetite
• Seizure (note: seizures can also be part of glioma itself)

Serious Side Effects and Warnings

1) Hepatotoxicity (Liver Injury Risk)

Voranigo can cause elevated liver enzymes (ALT/AST) and, in rare cases, serious liver injury. This is why clinicians monitor liver labs closely.
Signs that should trigger an urgent call to your care team can include: yellowing of the skin/eyes (jaundice), dark urine, severe nausea,
persistent abdominal pain (especially right upper belly), or unusual fatigue that feels “off” compared with your baseline.

2) Embryo-Fetal Toxicity (Pregnancy Warning)

Based on animal studies and mechanism, Voranigo can cause fetal harm. Pregnancy avoidance is typically emphasized during treatment.
Your team may recommend pregnancy testing before starting (when relevant) and effective contraception.

Common Lab Abnormalities (What Your Bloodwork Might Show)

Blood tests may show changes such as:

• Increased ALT/AST (liver enzymes)
• Increased GGT (another liver-related enzyme)
• Changes in potassium or other chemistries
• Lower neutrophils (a type of white blood cell)

Your doctor will interpret lab changes in context (your baseline labs, symptoms, other meds, alcohol use, underlying liver conditions, etc.).
A lab flag doesn’t automatically mean “stop the drug,” but it always means “pay attention.”

Monitoring: What Doctors Usually Check (and Why)

Expect routine monitoringespecially early on. Liver labs are commonly checked:

• Before starting
• Every 2 weeks for the first 2 months
• Monthly for the first 2 years
• Then as clinically indicated (more often if liver enzymes rise)

Yes, that sounds like a lot. But it’s the “catch things early” strategy. Think smoke detector, not fire alarm.

Dose Reductions (If Side Effects Show Up)

If side effects (especially liver enzyme elevations) become significant, clinicians may pause treatment, reduce the dose, or discontinue.
Dose reductions can step down (for many patients) from 40 mg daily to 20 mg daily, then to 10 mg daily if needed.
If a patient can’t tolerate the lowest dose, Voranigo is typically discontinued.

Drug Interactions: What to Avoid

Voranigo’s metabolism involves pathways that can be influenced by other medications and certain exposures. This is where your medication list
(including supplements) matters. A few key interaction themes:

CYP1A2 Inhibitors

Strong or moderate CYP1A2 inhibitors may raise vorasidenib levels and increase side effect risk. Clinicians generally try to avoid these,
and if they can’t be avoided, they may monitor more closely and adjust dosing if adverse effects occur.

CYP1A2 Inducers and Smoking Tobacco

Moderate CYP1A2 inducersand smoking tobaccomay lower vorasidenib levels and reduce antitumor activity.
If you needed another reason to quit smoking, add “don’t sabotage expensive brain-tumor medicine” to the list.

Certain CYP3A Substrates

Voranigo may lower levels of certain CYP3A substrate medications, especially where small concentration changes could reduce effectiveness.
Your clinician or pharmacist checks for these and may recommend alternatives.

Hormonal Contraceptives

Voranigo may reduce hormonal contraceptive concentrations, increasing the risk of contraceptive failure and breakthrough bleeding.
Nonhormonal contraception is often recommended during treatment (and for a period afterward) when pregnancy prevention is needed.

Voranigo Cost: What You Might Pay (and How People Lower It)

Let’s talk about the elephant in the pharmacy: Voranigo cost. New targeted cancer therapies are rarely cheap.
And because Voranigo is typically handled through specialty distribution, the “sticker price” can feel like a plot twist.

Typical Price Range

Cash prices vary by pharmacy, location, and supply chain. Public pricing tools may list a monthly supply (often 30 tablets) at
tens of thousands of dollars. This is not the amount most insured patients ultimately pay out of pocket, but it illustrates why
insurance approval and assistance programs matter.

What Affects Your Out-of-Pocket Cost?

• Insurance type: commercial vs. Medicare/Medicaid vs. marketplace plans
• Formulary status: whether Voranigo is covered and under what tier
• Prior authorization requirements: documentation of IDH mutation and diagnosis
• Deductible and out-of-pocket maximum: where you are in the calendar year
• Specialty pharmacy rules: some plans require specific specialty pharmacies

Ways People Reduce Cost (Legitimately)

Depending on eligibility, cost-lowering options can include:

• Manufacturer copay programs (often for commercially insured patients)
• Patient assistance programs (for certain uninsured/underinsured situations)
• Foundation support (availability varies and can be diagnosis-specific)
• Specialty pharmacy care teams that help coordinate benefits and appeals

Practical tip: when the specialty pharmacy calls, pick up. It’s not a scammer. It’s usually the person who can tell you whether
your prescription is cruising toward shipment or stuck in “prior authorization purgatory.”

Storage and Handling

• Store at room temperature (generally 68°F to 77°F; short excursions may be allowed).
• Keep in the original container, away from moisture, and out of reach of children.

FAQ: Quick Answers People Commonly Ask

Is Voranigo chemotherapy?

No. It’s a targeted therapy aimed at tumors with specific IDH mutations. That said, “not chemo” does not mean “no monitoring.”

Will Voranigo cure my glioma?

It is not typically described as curative. Its demonstrated value is in slowing progression and
delaying the need for next interventions in certain patients.

What side effect is the biggest deal?

The prescribing information emphasizes liver toxicity risk, which is why regular liver labs are a core part of treatment.

Can I drink alcohol on Voranigo?

Ask your oncologist. Because liver monitoring is central with Voranigo, many clinicians advise caution with alcohol.
Your recommendation may vary based on your baseline liver function and overall health.

Do I need tumor genetic testing?

YesVoranigo is for grade 2 astrocytoma/oligodendroglioma with a susceptible IDH1 or IDH2 mutation.
Your team typically determines this from tumor tissue testing.

Real-World Experiences: What Treatment Often Feels Like (About )

The most “real-world” part of taking Voranigo isn’t always the pill itselfit’s the rhythm that forms around it.
Most people don’t wake up thinking, “Today I’ll take an IDH inhibitor and contemplate molecular oncology.”
They wake up thinking, “Do we have groceries?” and “Is my MRI next week?” and “Why is my insurance portal allergic to logic?”

One common experience is the watchful waiting mind game. Many grade 2 glioma patients feel stuck between two stressful options:
treat aggressively now (which can carry lasting side effects), or delay and monitor (which can feel like waiting for the other shoe to drop).
Voranigo entered this conversation as a middle lane for some patientssomething active, but not automatically a leap to radiation/chemo.
People often describe it as “doing something” while trying to protect quality of life, especially if they’re working, parenting,
or simply trying to live like a human instead of a full-time patient.

Another frequent theme: lab work becomes a lifestyle. Early on, liver labs can be scheduled often,
and that can feel annoyinguntil you reframe it as a safety net. Some patients keep a simple checklist:
pill time, hydration, symptom notes, lab dates. It’s not glamorous, but it reduces anxiety because you’re tracking what matters.
Many also learn to recognize the difference between “normal tired” and “this tired feels different,” and they get comfortable
messaging their care team sooner rather than later.

Then there’s the side effect detective work. Fatigue, GI changes, and aches can have multiple causes:
the medication, the tumor, stress, sleep disruption, anti-seizure meds, or all of the above teaming up like a villain squad.
People who do best often treat symptom management like a collaboration: they tell the truth about what they’re feeling,
they bring a medication list (including supplements), and they ask practical questions like “What would make you want me to call right away?”
That last question is a cheat code.

Cost and access are their own saga. Many patients describe the first fill as the hardest: prior authorizations, specialty pharmacy calls,
benefit investigations, and sometimes appeals. Once approved, refills can become smootherthough insurance changes and calendar-year
deductibles can cause unpleasant surprises. A lot of patients (and caregivers) learn to keep a “paper trail” folder: test results showing
IDH mutation status, clinic notes, denial letters, approval letters, and the names of people they spoke with. It sounds extrauntil it saves
weeks of back-and-forth.

Finally, there’s the emotional layer: taking a targeted therapy can feel hopeful and heavy at the same time.
Hopeful because there’s a specific option aimed at the tumor’s biology. Heavy because it’s a reminder that the tumor is still part of life.
Many people say the best support comes from two places: a medical team that explains the “why” behind decisions, and a community (online or
local) that understands the unique long-haul nature of low-grade glioma care. In short: the medicine matters, but so does the system you
build around it.